BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 34102008)

  • 1. Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease.
    Cortez-Pinto H; Liberal R; Lopes S; Machado MV; Carvalho J; Dias T; Santos A; Agostinho C; Figueiredo P; Loureiro R; Martins A; Alexandrino G; Cotrim I; Leal C; Presa J; Mesquita M; Nunes J; Gouveia C; Vale AHE; Alves AL; Coelho M; Maia L; Pedroto I; Banhudo A; Pinto JS; Gomes MV; Oliveira J; Andreozzi V; Calinas F
    United European Gastroenterol J; 2021 Jul; 9(6):699-706. PubMed ID: 34102008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study.
    Örnolfsson KT; Lund SH; Olafsson S; Bergmann OM; Björnsson ES
    Scand J Gastroenterol; 2019 May; 54(5):609-616. PubMed ID: 31074667
    [No Abstract]   [Full Text] [Related]  

  • 3. Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study.
    Papastergiou V; Tsochatzis EA; Rodriguez-Peralvarez M; Thalassinos E; Pieri G; Manousou P; Germani G; Rigamonti C; Arvaniti V; Karatapanis S; Burroughs AK
    Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1354-64. PubMed ID: 24117847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
    Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
    Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment response to ursodeoxycholic acid in primary biliary cholangitis: A systematic review and meta-analysis.
    Gazda J; Drazilova S; Gazda M; Janicko M; Koky T; Macej M; Carbone M; Jarcuska P
    Dig Liver Dis; 2023 Oct; 55(10):1318-1327. PubMed ID: 36593158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy.
    Vespasiani-Gentilucci U; Rosina F; Pace-Palitti V; Sacco R; Pellicelli A; Chessa L; De Vincentis A; Barlattani M; Barlattani A; Feletti V; Mussetto A; Zolfino T; Russello M; Cozzolongo R; Garrucciu G; Niro G; Bacca D; Bertino G; Claar E; Ascione A; D'Adamo G; Adinolfi LE; Scifo G; Izzi A;
    Scand J Gastroenterol; 2019 Oct; 54(10):1274-1282. PubMed ID: 31564176
    [No Abstract]   [Full Text] [Related]  

  • 7. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
    Carbone M; Nardi A; Flack S; Carpino G; Varvaropoulou N; Gavrila C; Spicer A; Badrock J; Bernuzzi F; Cardinale V; Ainsworth HF; Heneghan MA; Thorburn D; Bathgate A; Jones R; Neuberger JM; Battezzati PM; Zuin M; Taylor-Robinson S; Donato MF; Kirby J; Mitchell-Thain R; Floreani A; Sampaziotis F; Muratori L; Alvaro D; Marzioni M; Miele L; Marra F; Giannini E; Gaudio E; Ronca V; Bonato G; Cristoferi L; Malinverno F; Gerussi A; Stocken DD; Cordell HJ; Hirschfield GM; Alexander GJ; Sandford RN; Jones DE; Invernizzi P; Mells GF;
    Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):626-634. PubMed ID: 30017646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis.
    Guo GY; Shi YQ; Wang L; Ren X; Han ZY; Guo CC; Cui LN; Wang JB; Zhu J; Wang N; Zhang J; Cai Y; Han Y; Zhou XM; Fan DM
    Aliment Pharmacol Ther; 2015 Jul; 42(2):221-30. PubMed ID: 25982180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study.
    Jones DEJ; Wetten A; Barron-Millar B; Ogle L; Mells G; Flack S; Sandford R; Kirby J; Palmer J; Brotherston S; Jopson L; Brain J; Smith GR; Rushton S; Jones R; Rushbrook S; Thorburn D; Ryder SD; Hirschfield G; ; Dyson JK
    EBioMedicine; 2022 Jun; 80():104068. PubMed ID: 35609437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary biliary cholangitis with normal alkaline phosphatase: A neglected clinical entity challenging current guidelines.
    Terziroli Beretta-Piccoli B; Stirnimann G; Mertens J; Semela D; Zen Y; Mazzucchelli L; Voreck A; Kolbus N; Merlo E; Di Bartolomeo C; Messina P; Cerny A; Costantini S; Vergani D; Mieli-Vergani G;
    J Autoimmun; 2021 Jan; 116():102578. PubMed ID: 33229138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
    Schattenberg JM; Pares A; Kowdley KV; Heneghan MA; Caldwell S; Pratt D; Bonder A; Hirschfield GM; Levy C; Vierling J; Jones D; Tailleux A; Staels B; Megnien S; Hanf R; Magrez D; Birman P; Luketic V
    J Hepatol; 2021 Jun; 74(6):1344-1354. PubMed ID: 33484775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Response to Primary Biliary Cholangitis Treatment: Influencing Factors and the Role in Prognosis Prediction].
    Liu Y; Fan X; Shen Y; Men R; Guo Y; Yang L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Sep; 54(5):930-936. PubMed ID: 37866948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.
    Lammers WJ; Hirschfield GM; Corpechot C; Nevens F; Lindor KD; Janssen HL; Floreani A; Ponsioen CY; Mayo MJ; Invernizzi P; Battezzati PM; Parés A; Burroughs AK; Mason AL; Kowdley KV; Kumagi T; Harms MH; Trivedi PJ; Poupon R; Cheung A; Lleo A; Caballeria L; Hansen BE; van Buuren HR;
    Gastroenterology; 2015 Dec; 149(7):1804-1812.e4. PubMed ID: 26261009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
    Hegade VS; Khanna A; Walker LJ; Wong LL; Dyson JK; Jones DEJ
    Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis.
    Hao YL; Bian ZL; Ju LL; Liu Y; Qin G
    Dig Dis Sci; 2020 Feb; 65(2):470-479. PubMed ID: 31377883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment.
    Chen J; Xue D; Gao F; Tao L; Li Y; Zhang Q; Wang R; Sun L; Yang X; Liu Y; Zhu B; Niu S; Wang X
    Eur J Gastroenterol Hepatol; 2018 Nov; 30(11):1352-1360. PubMed ID: 29889683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of the Scheuer histological staging system for primary biliary cholangitis in Japanese patients.
    Namisaki T; Moriya K; Kitade M; Kawaratani H; Takeda K; Okura Y; Takaya H; Nishimura N; Seki K; Kaji K; Sato S; Sawada Y; Yamao J; Mitoro A; Uejima M; Mashitani T; Shimozato N; Nakanishi K; Furukawa M; Saikawa S; Kubo T; Yoshiji H
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):23-30. PubMed ID: 27755231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of ursodeoxycholic acid for primary biliary cholangitis: Experience from a tertiary care centre in Saudi Arabia.
    AlWabel AH; Peedikayil M; AlNasser S; AlHusaini K; AlHekail O; Alqahtani SA; AlTraif IH; AlAshgar H
    Saudi J Gastroenterol; 2023; 29(2):135-140. PubMed ID: 35229756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
    Corpechot C; Abenavoli L; Rabahi N; Chrétien Y; Andréani T; Johanet C; Chazouillères O; Poupon R
    Hepatology; 2008 Sep; 48(3):871-7. PubMed ID: 18752324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.
    Harms MH; de Veer RC; Lammers WJ; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Trivedi PJ; Hirschfield GM; Pares A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Hansen BE; Buuren HRV; van der Meer AJ
    Gut; 2020 Aug; 69(8):1502-1509. PubMed ID: 31843787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.